cholestyramine resin has been researched along with bezafibrate in 21 studies
| Studies (cholestyramine resin) | Trials (cholestyramine resin) | Recent Studies (post-2010) (cholestyramine resin) | Studies (bezafibrate) | Trials (bezafibrate) | Recent Studies (post-2010) (bezafibrate) |
|---|---|---|---|---|---|
| 2,669 | 342 | 190 | 1,335 | 267 | 324 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (33.33) | 18.7374 |
| 1990's | 12 (57.14) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviram, M; Brook, GJ; Hoffman, R | 1 |
| Ansoleaga, J; Joven, J; Masana, L; Vilella, E | 1 |
| Shapiro, DR; Walker, JF | 1 |
| Bergmann, S; Fischer, S; Fücker, K; Gehrisch, S; Hanefeld, M; Jaross, W; Lang, PD; Leonhardt, W | 1 |
| Caslake, MJ; Cruickshank, A; Demant, T; Kilday, C; Lorimer, AR; Packard, CJ; Series, JJ; Shepherd, J | 1 |
| Kostner, GM | 1 |
| Betteridge, J; Curtis, LD; Dickson, AC; Ling, KL | 1 |
| Holler, HD; Lang, PD; Müller, S; Steinhagen-Thiessen, E | 1 |
| Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M | 1 |
| Maxwell, RE; Nawrocki, JW; Uhlendorf, PD | 1 |
| Canzler, H | 1 |
| Eliav, O; Friedlander, Y; Leitersdorf, E; Pfister, P; Schurr, D | 1 |
| Eliav, O; Leitersdorf, E; Muratti, EN; Peters, TK | 1 |
| Hirakoso, K; Kohno, T; Mori, T; Ohtani, A; Takashima, K; Takeyama, S | 1 |
| Dann, EJ; Eisenberg, S; Eliav, O; Leitersdorf, E; Meiner, V; Muratti, EN; Peters, TK; Sehayek, E; Stein, Y | 1 |
| Leitersdorf, E; Muratti, EN; Peters, TK | 1 |
| Jokubaitis, LA | 2 |
| Anzivino, C; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Kienle, MG; Loria, P; Pellegrini, E; Ricchi, M; Zambianchi, L | 1 |
| Düll, MM; Kremer, AE | 1 |
3 review(s) available for cholestyramine resin and bezafibrate
| Article | Year |
|---|---|
The affection of lipoprotein-a by lipid lowering drugs.
Topics: Arteriosclerosis; Bezafibrate; Cholestyramine Resin; Hormones; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins; Neomycin; Niacin; Nicotinic Acids; Stanozolol | 1988 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
Management of Chronic Hepatic Itch.
Topics: Analgesics, Opioid; Anion Exchange Resins; Antipruritics; Bezafibrate; Carrier Proteins; Cholagogues and Choleretics; Cholestasis; Cholestyramine Resin; Chronic Disease; Cytochrome P-450 Enzyme Inducers; Drainage; Humans; Hypolipidemic Agents; Membrane Glycoproteins; Methylamines; Narcotic Antagonists; Prevalence; Pruritus; Rifampin; Thiazepines; Ursodeoxycholic Acid | 2018 |
11 trial(s) available for cholestyramine resin and bezafibrate
| Article | Year |
|---|---|
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic | 1990 |
Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.
Topics: Adult; Bezafibrate; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Triglycerides | 1989 |
Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia.
Topics: Adult; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Random Allocation | 1988 |
Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia.
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Lipoproteins, VLDL; Male; Middle Aged; Random Allocation; Triglycerides | 1987 |
High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Delayed-Action Preparations; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Longitudinal Studies; Placebos; Safety; Triglycerides | 1995 |
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Artery Disease; Creatine Kinase; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Male; Middle Aged; Patient Compliance; Placebos; Safety; Triglycerides | 1995 |
Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hyperlipoproteinemia Type II; Indoles; Male; Middle Aged; Myositis; Placebos; Safety; Single-Blind Method; Triglycerides | 1994 |
Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Cohort Studies; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lipids; Lipoproteins; Male; Middle Aged; Retrospective Studies; Time Factors | 1994 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1994 |
8 other study(ies) available for cholestyramine resin and bezafibrate
| Article | Year |
|---|---|
Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.
Topics: Adult; Animals; Bezafibrate; Cells, Cultured; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Esterification; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Macrophages; Male; Malondialdehyde; Mice; Middle Aged; Pravastatin; Vitamin E | 1992 |
Low density lipoprotein receptor levels and the response to dietary and pharmacological intervention in polygenic hypercholesterolemia.
Topics: Adult; Apolipoproteins B; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Humans; Hypercholesterolemia; Lymphocytes; Middle Aged; Receptors, LDL | 1991 |
Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients.
Topics: Adult; Bezafibrate; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged | 1986 |
Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
Topics: Animals; Anticholesteremic Agents; Bezafibrate; Caprylates; Carbon Radioisotopes; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Lovastatin; Male; Mevalonic Acid; Naphthalenes; Pentanoic Acids; Rats; Rats, Inbred F344; Sterols; Valerates | 1983 |
[Drug therapy of hypercholesterinemias (author's transl)].
Topics: Adult; Bezafibrate; Cholestyramine Resin; Clofibric Acid; Colestipol; Dextrothyroxine; Fenofibrate; Humans; Hypercholesterolemia; Neomycin; Nicotinic Acids; Sitosterols | 1980 |
The hypocholesterolemic action of TA-7552 and its effects on cholesterol metabolism in the rat.
Topics: Animals; Bezafibrate; Bile Acids and Salts; Cholestanol; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholestyramine Resin; Chromatography, Gas; Feces; Liver; Naphthols; Probucol; Rats; Rats, Sprague-Dawley | 1994 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Complement C4; Data Interpretation, Statistical; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Reference Standards; Simvastatin | 2008 |